Real-world Evidence With CDK4/6 Inhibitors

This segment explores how real-world evidence complements clinical trials by providing insight into broader patient populations. Panelists note that findings from observational studies confirm the effectiveness and safety of CDK4/6 inhibitors in routine practice, even among patients with comorbidities or socioeconomic challenges who are often underrepresented in trials.

A key point of discussion is the consistent benefit seen across subgroups, including those with bone-only disease and patients from disadvantaged backgrounds. The data show that treatment outcomes remain robust when monitoring and adherence support are prioritized. Pharmacists play a vital role in bridging access gaps, assisting with affordability programs, and ensuring that patients in community settings receive consistent care.

By integrating real-world data into decision-making, clinicians can refine patient selection and anticipate adherence challenges early. The panel concludes that expanding equitable access and tailoring monitoring strategies will enhance outcomes in everyday oncology practice.